Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29880880 | 1.00 | NR1H4 (0.56) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL1885524 | 0.90 | NR1H4 (0.60) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL29880561 | 0.90 | NR1H4 (0.60) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL1891959 | 0.90 | NR1H4 (0.54) | NR1H4LMNATSHRPKMALDH1A1 | |
| SCHEMBL16354126 | 0.88 | LMNA (0.52) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL29880959 | 0.87 | NR1H4 (0.59) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL1885228 | 0.87 | NR1H4 (0.59) | NR1H4LMNATSHRMAPK1PKM | |
| SCHEMBL1881182 | 0.86 | NR1H4 (0.61) | NR1H4LMNATSHRALDH1A1MAPT | |
| SCHEMBL29880988 | 0.86 | NR1H4 (0.61) | NR1H4LMNATSHRALDH1A1MAPT | |
| SCHEMBL1893687 | 0.86 | NR1H4 (0.59) | NR1H4LMNATSHRPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262785-B1 | BENZOFURANE DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | claimed |
| EP-2262785-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127321-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH, (DE) | 2009-10-22 | — | — | WO | claimed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | claimed |
| EP-3043865-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INST NAT SANTE RECH MED (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3711762-A1 | A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-09-23 | — | — | EP | disclosed |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-11 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| EP-3043865-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036442-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-03-19 | — | — | WO | disclosed |
| EP-2262785-B1 | BENZOFURANE DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2262785-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009127321-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH, (DE) | 2009-10-22 | — | — | WO | disclosed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885LMNA 3746/4885TSHR 2137/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | NR1H4 1/4885LMNA 3711/4885TSHR 2004/4885 |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | FXR1, FXR2, NR1H4 | NR1H4 3/4885LMNA 4276/4885TSHR 1235/4885 |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | NR1H4, FXR2, FXR1 | NR1H4 1/4885LMNA 3746/4885TSHR 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.